Suppr超能文献

2009年至2010年肯尼亚患者中1型人类免疫缺陷病毒共受体嗜性概况

Profile of HIV type 1 coreceptor tropism among Kenyan patients from 2009 to 2010.

作者信息

Nyamache Anthony Kebira, Muigai Anne W T, Ng'ang'a Zipporah, Khamadi Samoel A

机构信息

Department of Plant and Microbial Sciences, Kenyatta University, Nairobi, Kenya.

出版信息

AIDS Res Hum Retroviruses. 2013 Aug;29(8):1105-9. doi: 10.1089/aid.2012.0284. Epub 2013 May 21.

Abstract

A switch of HIV coreceptor usage from CCR5 to CXCR4 occurs in AIDS pathogenesis and may play a critical role in the use of entry inhibitors. To determine the potential usefulness of maraviroc and other CCR5 antagonists among drug-naive and experienced patients in Kenya, the env-C2-V3 gene was successfully sequenced in samples from 176 (98 men and 78 female) consenting subjects between January 2009 and December 2012. In silico CPSSM, webPSSM/, and (ds) Kernel tools were used in predicting coreceptor usage. On the basis of the env V3 loop sequences, 84.1% (148) were reported with R-5 tropism, 4.5% (5) were dual tropic, while 13.4% (23) were of X4 tropism. However, similar to previous studies conducted in Kenya on genetic diversity, HIV-1 subtype A1 (73.9%; 130/176) still remains the most dominant subtype. The high levels of R5 tropism among the studied Kenyan infected populations suggested the potential use of CCR5 antagonists as new therapeutic options in Kenya.

摘要

在艾滋病发病机制中,HIV共受体使用情况会从CCR5转换为CXCR4,这可能在进入抑制剂的使用中起关键作用。为了确定马拉维若及其他CCR5拮抗剂在肯尼亚未接受过治疗和接受过治疗的患者中的潜在效用,2009年1月至2012年12月期间,成功对176名(98名男性和78名女性)同意参与研究的受试者的样本进行了env-C2-V3基因测序。利用计算机CPSSM、webPSSM/和(ds)内核工具预测共受体使用情况。根据env V3环序列报告,84.1%(148例)为R-5嗜性,4.5%(5例)为双嗜性,而13.4%(23例)为X4嗜性。然而,与此前在肯尼亚进行的关于基因多样性的研究相似,HIV-1 A1亚型(73.9%;130/176)仍然是最主要的亚型。在肯尼亚受研究的感染人群中,R5嗜性水平较高,这表明CCR5拮抗剂有可能作为新的治疗选择在肯尼亚使用。

相似文献

本文引用的文献

7
Coreceptors and HIV-1 pathogenesis.辅助受体与 HIV-1 发病机制。
Curr HIV/AIDS Rep. 2011 Mar;8(1):45-53. doi: 10.1007/s11904-010-0069-x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验